Clinical trials approval for Redx Pharma

Drug discovery and development company Redx Pharma – fighting itself for survival – has received approval of clinical trials for its treatment for people suffering from gastric, biliary and pancreatic cancer.

The AIM-listed company which relocated from Liverpool to Alderley Park in late 2016, but which was forced into administration last month, has been given clearance by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and Ethics Review Committee for its clinical trial application for the Porcupine inhibitor RXC004.

RXC004 is an oral, small molecule Porcupine inhibitor in development as a monotherapy for difficult to treat cancers.